# What a 2026 cohort study found about circulating IGF-1 and epilepsy risk

- Article ID: research-188
- Product: IGF-1 Human (igf-1-human-625)
- Canonical page: https://heritagebiolabs.com/research-library/articles/188-what-a-2026-cohort-study-found-about-circulating-igf-1-and-epilepsy-risk
- Product collection: https://heritagebiolabs.com/research-library/products/igf-1-human
- Product page: https://heritagebiolabs.com/product/igf-1-human-625
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Longer chains can also act as signaling hormones. Human insulin-like growth factor 1 (IGF-1) is a 70-amino-acid hormone involved in growth and metabolism. A 2026 study looked at naturally circulating IGF-1 and asked whether blood concentrations measured before a diagnosis were associated with later epilepsy. [1, 2]

Researchers analyzed 466,857 UK Biobank participants with baseline IGF-1 measurements. During more than 15 years of follow-up, the study identified 4,532 people who developed epilepsy. The investigators used statistical models to adjust for several characteristics and looked at how the relationship changed across the range of measured concentrations. Lower blood IGF-1 was associated with a higher rate of new epilepsy diagnoses. The relationship was stronger at lower concentrations and appeared to flatten higher in the range. [1]

The study also asked a related but separate question about cognition. In participants who already had epilepsy, some initial cognitive associations did not remain statistically clear after the researchers adjusted for the number of comparisons. Analyses of cognitive performance in the larger cohort suggested associations in several domains, but those findings were not specific to people with epilepsy. Taken together, the data were clearer for the association with later epilepsy than for the cognitive outcomes. [1]

This was an observational human study. Researchers measured blood hormone concentrations and followed health records. They did not assign participants to receive IGF-1 or experimentally change their concentrations. Different health conditions or other characteristics can affect both a blood marker and a later diagnosis, even after a statistical model accounts for known factors. A blood concentration also describes the circulating hormone at the time of sampling and does not directly measure its activity in the brain. [1]

The result supports further work on whether IGF-1 could help researchers understand risk. It does not establish that changing circulating IGF-1 would change seizure risk or cognitive performance. Prescription mecasermin, a recombinant version of full-length human IGF-1, has defined U.S. indications for certain pediatric growth disorders. The 2026 cohort did not test that medicine. [1, 2]

## Sources

1. Guo J et al. Serum insulin-like growth factor-1 and its association with epilepsy risk and cognitive function. Acta Epileptologica (publication 2026-10-01). <https://link.springer.com/article/10.1186/s42494-026-00274-2>
2. Eton Pharmaceuticals, Inc. INCRELEX (mecasermin) injection, for subcutaneous use. DailyMed (label effective 2026-05-18). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 038 - Human Relaxin-2 and IGF-1 Human.docx; article 188; content SHA-256 656584d30acfa4166c8eda5c186013a16e609f3ba90e510d3ef2e14d1ec0d776.
